Is MOTS-c Legal in Texas?

What MOTS-c Is and Why Its Legal Status Matters

MOTS-c is a 16-amino-acid mitochondria-derived peptide first identified in a 2015 paper by Lee et al. Published in Cell Metabolism ([1]). It is encoded within the mitochondrial 12S rRNA gene, not a nuclear gene, which makes it structurally distinct from most peptides studied in clinical research. Early animal data suggested it improves insulin sensitivity, reduces obesity-related metabolic dysfunction, and may slow aspects of cellular aging, but human clinical trials remain limited and preliminary.

Why the Legal Question Is Genuinely Complicated

Because MOTS-c is not a synthetic analog of a scheduled substance and does not appear on any federal controlled substance schedule, some vendors and online forums describe it as freely legal. That framing is misleading. Under the FD&C Act, any article "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease" or intended to "affect the structure or function of the body" meets the statutory definition of a drug ([2]). Selling MOTS-c to humans with those claims, without an approved New Drug Application (NDA), constitutes marketing an unapproved drug, which is a federal violation regardless of which state the buyer lives in.

The Research-Chemical Loophole and Its Real Limits

Some suppliers sell MOTS-c labeled "for research use only, not for human consumption." This carve-out is real but narrow. The FDA evaluates the totality of circumstances, including marketing language, website context, and customer communications, to determine whether a product is actually intended for human use. If a vendor is implying or directly stating that buyers should inject MOTS-c, the "research use only" label does not provide legal shelter for the seller or, in some interpretations, the buyer.

Federal Regulatory Framework: FDA, 503A, and 503B

Understanding MOTS-c's Texas status requires understanding the two federal compounding pathways that govern how pharmacies can prepare non-FDA-approved peptides for patients.

Section 503A: Traditional Compounding Pharmacies

Under Section 503A of the FD&C Act, a licensed pharmacist at a state-licensed compounding pharmacy may prepare a compounded drug without an approved NDA, provided several conditions are met ([3]). One key condition: the bulk drug substance used must either be the active ingredient of an FDA-approved drug, appear on a specific FDA-published list of bulk substances that may be used in compounding, or be subject to a United States Pharmacopeia (USP) monograph.

MOTS-c does not satisfy any of those three criteria. It is not the active ingredient in any approved drug. There is no USP monograph for it. It has not been placed on the FDA's 503A bulk substance nominee list as an approved substance. The FDA maintains a running list of nominated bulk substances and their evaluation status; as of the date of this article's last review, MOTS-c has not been approved for 503A compounding use ([4]).

Section 503B: Outsourcing Facilities

Section 503B covers larger outsourcing facilities that compound in bulk without patient-specific prescriptions and distribute to hospitals and clinics. The rules are, if anything, stricter: bulk substances must appear on the FDA's affirmative 503B bulk list ([5]). MOTS-c does not appear there either.

The practical outcome is straightforward. No US compounding pharmacy operating within federal law can currently make MOTS-c for patient administration, whether the patient is in Texas or any other state.

FDA Enforcement History With Peptides

The FDA has acted repeatedly against compounders producing unapproved peptides. In 2023, the FDA released updated guidance warning that certain peptides, including BPC-157 and some others, were being compounded without legal authority ([6]). MOTS-c has not yet been the subject of a named enforcement letter, but that absence of a specific letter does not mean compounding it is permitted. The regulatory default under the FD&C Act is prohibition unless a substance is explicitly authorized.

Texas State Law: What the Texas State Board of Pharmacy Actually Says

Texas does not have a standalone statute that specifically addresses MOTS-c. Searching the Texas Occupations Code, the Texas Health and Safety Code, and the Texas Administrative Code (Title 22, Part 15, Texas State Board of Pharmacy rules) returns no result specific to this peptide.

How Texas Pharmacy Law Interfaces with Federal Rules

Texas pharmacy law generally mirrors and defers to federal compounding standards. Texas Occupations Code Chapter 558 governs pharmacy practice, and Texas Administrative Code Title 22, Chapter 291 addresses sterile compounding. Those rules require Texas pharmacies performing sterile compounding to comply with USP Chapter 797 standards and to use only substances legally permissible under federal law ([7]). Because MOTS-c is not legally permissible under federal 503A or 503B pathways, a Texas-licensed sterile compounding pharmacy cannot compound it for patient use without violating both federal rules and, by extension, state pharmacy board standards.

The Texas Medical Practice Act and Physician Prescribing

Under the Texas Medical Practice Act (Texas Occupations Code Chapter 157), a licensed physician may prescribe drugs in the course of legitimate medical practice. However, a prescription is only legally fillable if a licensed pharmacy can legally dispense the substance. Since no US pharmacy can currently compound MOTS-c under federal law, a Texas physician writing a prescription for it would have nowhere to send it that could legally fill it. The prescription itself is not independently a crime, but the practical pathway to a patient receiving it through a licensed US pharmacy does not currently exist.

Physician-Administered Gray Areas

Some clinics have attempted to import compounded peptides from international pharmacies, particularly those operating in Mexico or Canada. Importing unapproved drug products for commercial purposes violates federal law. The FDA does operate a personal importation policy for some unapproved drugs, allowing individuals to import a 90-day personal supply under limited circumstances, but that policy specifically excludes products the FDA has determined pose significant risks and products marketed for commercial purposes ([8]). Using that pathway to supply a clinical practice is not within the policy's scope.

The FDA Bulk Substance Nomination Process: A Path to Future Legality

The FDA's 503A bulk substance evaluation process is the primary mechanism by which a peptide like MOTS-c could eventually become legally compoundable. Stakeholders, including physicians, patients, or manufacturers, may nominate a substance. The FDA then evaluates it on three criteria: whether there is a clinical need, whether the substance can be compounded safely, and whether it is used in an FDA-approved drug that would make compounding inappropriate.

Current Nomination Status

As of this article's last review date, MOTS-c has not completed an FDA 503A evaluation that results in approval. The FDA's 503A bulk substance list is publicly accessible ([4]). Any reader checking that page after this article's publication date should look for a status change, because the list is updated periodically as FDA review progresses.

What a Positive Evaluation Would Change

If the FDA were to add MOTS-c to the 503A bulk substances list, Texas-licensed 503A compounding pharmacies could then prepare it for individual patients with a valid prescription from a licensed Texas physician. The FDA's placement of a substance on that list does not create an approved drug. It creates a legal compounding pathway, which is a meaningful but more limited status.

How Telehealth Providers and Peptide Clinics Are Navigating This

Several telehealth companies and peptide-focused clinics currently offer peptides to patients across Texas. The legal peptides they can offer are those that either appear on the FDA's 503A approved bulk list or qualify through other pathways. Common examples include sermorelin, ipamorelin, and CJC-1295, which are prescribed and compounded under circumstances that differ from MOTS-c's current status.

What Legitimate Telehealth Can and Cannot Do for MOTS-c

A legitimate, law-abiding telehealth provider operating in Texas cannot currently prescribe MOTS-c through a US-licensed compounding pharmacy. Any telehealth provider claiming otherwise is either misinformed about the regulatory framework or is directing patients toward sources that fall outside licensed US pharmacy oversight. Patients should ask any provider: "Which 503A or 503B-listed pharmacy will fill this prescription?" If the answer is vague or the provider points to a foreign pharmacy, that is a warning sign worth taking seriously.

Risks of Obtaining MOTS-c From Unregulated Sources

Research-chemical suppliers ship MOTS-c as a lyophilized powder, often with a certificate of analysis. That certificate tests for purity using high-performance liquid chromatography, but it does not test for endotoxins, pyrogens, or sterility, which are the tests required before any compound is safe for injection. A 2021 analysis published in Drug Testing and Analysis found that a substantial portion of peptide products purchased from research-chemical suppliers contained impurities or concentrations that differed from label claims ([9]). Injecting a non-sterile preparation carries risks of abscess, septicemia, and endotoxin-mediated systemic inflammation.

Clinical Research Background on MOTS-c

While the legal situation currently limits patient access, the science behind MOTS-c is worth understanding, especially because the research field may eventually support an NDA or 503A nomination.

Metabolic Effects in Animal Models

The original 2015 Lee et al. Study in Cell Metabolism (N = multiple mouse cohorts) showed that systemic MOTS-c administration reduced diet-induced obesity, improved insulin signaling in skeletal muscle, and activated AMPK pathways ([1]). A 2019 follow-up by the same group demonstrated that MOTS-c levels decline with age in both mice and humans, and that exogenous administration in aged mice improved exercise capacity and metabolic flexibility ([10]).

Early Human Observational Data

A cross-sectional study published in 2019 in Aging measured circulating MOTS-c levels in 152 human subjects across age groups and found a significant inverse correlation between plasma MOTS-c and fasting insulin (P<0.01), with levels approximately 35% lower in adults over age 65 compared with adults aged 20 to 35 ([11]). This is observational data. It establishes association, not causation, and no randomized controlled trial in humans has yet established a therapeutic dose or confirmed clinical benefit.

Where the Research Gaps Are

No phase II or phase III human RCT for MOTS-c has been registered or completed as of this article's last review date. ClinicalTrials.gov searches for "MOTS-c" return early-phase or observational protocols only. Without phase III human safety and efficacy data, the FDA has no basis on which to approve MOTS-c as a drug, and the 503A evaluation process would require at minimum a demonstration of clinical need backed by controlled human data.

What Texas Patients and Physicians Should Do Right Now

The practical guidance here is specific and actionable.

For Patients

If you are interested in metabolic peptide therapy and live in Texas, ask your physician about legal compoundable options. Sermorelin, ipamorelin/CJC-1295 combinations, and tesamorelin (FDA-approved for HIV-associated lipodystrophy) all have more established legal pathways and more human data than MOTS-c currently does. Purchasing MOTS-c from an online research-chemical vendor and self-injecting it exposes you to real infection risks and receives no legal protection if something goes wrong.

For Physicians

Writing a prescription for MOTS-c does not itself violate the Texas Medical Practice Act, but directing a patient toward an unregulated foreign supplier to fill that prescription could implicate professional conduct standards. The Texas Medical Board has broad authority to discipline physicians for conduct that "fails to meet the standard of care." Recommending a non-sterile research chemical for injection may meet that threshold. Physicians should consult the Texas Medical Board's guidance on off-label prescribing and compounding before proceeding.

For Clinics Considering Adding MOTS-c to Their Protocols

Check the FDA 503A bulk substance list directly at the FDA website before making any clinical or commercial decision ([4]). If MOTS-c's status changes, that page will reflect it. Do not rely on third-party summaries, vendor assurances, or forum posts for compliance decisions.

The FDA's 503A bulk substance list, accessible at fda.gov, is the single authoritative source for whether MOTS-c may be legally compounded for a Texas patient on any given day. Check it before acting.